Abstract
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
KCNQ channel openers reverse depressive symptoms via an active resilience mechanism
Nature Communications Open Access 24 May 2016
-
The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands
Cell Research Open Access 25 June 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nature Rev. Drug Discov. 9, 68–82 (2010).
Rostock A. et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23, 211–223 (1996).
Rundfeldt, C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. 336, 243–249 (1997).
US Food and Drug Administration. FDA labeling information — Potiga. FDA website [online], (2011).
European Medicines Agency (EMA). European Public Assessment Report — Trobalt. EMA website [online], (2011).
Porter, R. J. et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68, 1197–2004 (2007).
French, J. A. et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76, 1555–1563 (2011).
Brodie, M. J. et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75, 1817–1824 (2010).
Schmidt, D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 11, 9–11 (2011).
Faught, E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 11, 75–78 (2011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Stafstrom, C., Grippon, S. & Kirkpatrick, P. Ezogabine (retigabine). Nat Rev Drug Discov 10, 729–730 (2011). https://doi.org/10.1038/nrd3561
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3561
This article is cited by
-
A small-molecule activation mechanism that directly opens the KCNQ2 channel
Nature Chemical Biology (2024)
-
Molecular basis for ligand activation of the human KCNQ2 channel
Cell Research (2021)
-
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder
Molecular Psychiatry (2020)
-
HCN Channel Targets for Novel Antidepressant Treatment
Neurotherapeutics (2017)
-
KCNQ channel openers reverse depressive symptoms via an active resilience mechanism
Nature Communications (2016)